HEALTH CARE
- Share via
From Times Staff and Wire Reports
Genentech Gets Permanent Injunction: Genentech Inc. of South San Francisco said it was granted a permanent injunction against Wellcome that prohibits the British drug giant from making the clot-dissolving drug t-PA until 2005. Since 1988, Genentech has been battling Wellcome over patent rights to t-PA. Genentech, one of the largest biotechnology companies, sells t-PA under the brand name Activase, which brought in 33% of the company’s $169.8 million in second-quarter sales.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
